Stay updated with breaking news from Comera Life Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Having patients give themselves injections, when possible, not only saves clinic time and expense, but also spares the patients a trip to the clinic, of course, and often a copay.
Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA – Get Rating) was the recipient of a large decline in short interest in the month of May. As of May 31st, there was short interest totalling 39,200 shares, a decline of 12.3% from the May 15th total of 44,700 shares. Currently, 0.5% of the company’s shares are short […]
Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA – Get Rating) saw a significant increase in short interest in May. As of May 15th, there was short interest totalling 44,700 shares, an increase of 5.4% from the April 30th total of 42,400 shares. Currently, 0.5% of the company’s stock are short sold. Based on an average daily […]
Comera Life Sciences (NASDAQ:CMRA – Get Rating) is one of 995 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Comera Life Sciences to related businesses based on the strength of its valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership. Profitability This table compares […]
- Significant progress in Comera's ongoing research collaboration with Regeneron, a leading U.S. biotechnology company - - Further development of Comera's pipeline candidate CLS-001 (SQ vedolizumab),